Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers
Abstract
:1. Introduction
2. Results
2.1. Subsection
2.1.1. Patient and Tumor Characteristics in Seven Human Cancers
2.1.2. Profiles of Immune Infiltration and RT Outcome
2.1.3. Immune Cell Subpopulations and RT Outcomes
2.1.4. BRCA Radiosensitivity Signature Based on Immune Infiltration
3. Discussion
4. Materials and Methods
4.1. Data Acquisition
4.2. Inferring Tumor Purity
4.3. CIBERSORT Deconvolution Algorithm
4.4. BRCA Radiosensitivity Signature Construction and Validation
4.5. Statistics and Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Orth, M.; Lauber, K.; Niyazi, M.; Friedl, A.A.; Li, M.L.; Maihofer, C.; Schuttrumpf, L.; Ernst, A.; Niemoller, O.M.; Belka, C. Current concepts in clinical radiation oncology. Radiat. Environ. Bioph. 2014, 53, 1–29. [Google Scholar] [CrossRef] [Green Version]
- Xiao, Y.; Rosen, M. The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial. Transl. Lung Cancer Res. 2017, 6, 621–624. [Google Scholar] [CrossRef] [Green Version]
- Baumann, M.; Krause, M.; Overgaard, J.; Debus, J.; Bentzen, S.M.; Daartz, J.; Richter, C.; Zips, D.; Bortfeld, T. Radiation oncology in the era of precision medicine. Nat. Rev. Cancer 2016, 16, 234–249. [Google Scholar] [CrossRef]
- Kunos, C.A.; Coleman, C.N. Current and Future Initiatives for Radiation Oncology at the National Cancer Institute in the Era of Precision Medicine. Int. J. Radiat. Oncol. Biol. Phys. 2018, 102, 18–25. [Google Scholar] [CrossRef] [Green Version]
- Quon, H.; McNutt, T.; Lee, J.; Bowers, M.; Jiang, W.; Lakshminarayanan, P.; Cheng, Z.; Han, P.J.; Hui, X.; Moore, J.; et al. Needs and Challenges for Radiation Oncology in the Era of Precision Medicine. Int. J. Radiat. Oncol. 2019, 103, 809–817. [Google Scholar] [CrossRef]
- He, K.; Zhang, S.; Shao, L.L.; Yin, J.C.; Wu, X.; Shao, Y.W.; Yuan, S.; Yu, J. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Lett. 2019. [Google Scholar] [CrossRef]
- Eschrich, S.A.; Pramana, J.; Zhang, H.L.; Zhao, H.Y.; Boulware, D.; Lee, J.H.; Bloom, G.; Rocha-Lima, C.; Kelley, S.; Calvin, D.P.; et al. A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis after Chemoradiation. Int. J. Radiat. Oncol. 2009, 75, 489–496. [Google Scholar] [CrossRef] [Green Version]
- Speers, C.; Zhao, S.; Liu, M.L.; Bartelink, H.; Pierce, L.J.; Feng, F.Y. Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. Clin. Cancer Res. 2015, 21, 3667–3677. [Google Scholar] [CrossRef] [Green Version]
- Poynter, L.; Galea, D.; Veselkov, K.; Mirnezami, A.; Kinross, J.; Nicholson, J.; Takats, Z.; Darzi, A.; Mirnezami, R. Network Mapping of Molecular Biomarkers Influencing Radiation Response in Rectal Cancer. Clin. Colorectal. Canc. 2019, 18, E210–E222. [Google Scholar] [CrossRef] [Green Version]
- Walle, T.; Martinez Monge, R.; Cerwenka, A.; Ajona, D.; Melero, I.; Lecanda, F. Radiation effects on antitumor immune responses: Current perspectives and challenges. Ther. Adv. Med. Oncol. 2018, 10, 1758834017742575. [Google Scholar] [CrossRef]
- Tanic, M.; Krivokuca, A.; Cavic, M.; Mladenovic, J.; Plesinac Karapandzic, V.; Beck, S.; Radulovic, S.; Susnjar, S.; Jankovic, R. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer. Radiat. Oncol. 2018, 13, 193. [Google Scholar] [CrossRef]
- Stapleton, S.; Jaffray, D.; Milosevic, M. Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery. Adv. Drug Deliv. Rev. 2017, 109, 119–130. [Google Scholar] [CrossRef]
- Binnewies, M.; Roberts, E.W.; Kersten, K.; Chan, V.; Fearon, D.F.; Merad, M.; Coussens, L.M.; Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Hedrick, C.C.; et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018, 24, 541–550. [Google Scholar] [CrossRef]
- Menon, H.; Ramapriyan, R.; Cushman, T.R.; Verma, V.; Kim, H.H.; Schoenhals, J.E.; Atalar, C.; Selek, U.; Chun, S.G.; Chang, J.Y.; et al. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol. 2019, 10, 193. [Google Scholar] [CrossRef] [Green Version]
- Lippitz, B.E.; Harris, R.A. A translational concept of immuno-radiobiology. Radiother Oncol. 2019, 140, 116–124. [Google Scholar] [CrossRef] [Green Version]
- Stahl, D.; Gentles, A.J.; Thiele, R.; Gutgemann, I. Prognostic profiling of the immune cell microenvironment in Ewing s Sarcoma Family of Tumors. Oncoimmunology 2019, 8, e1674113. [Google Scholar] [CrossRef] [Green Version]
- Yang, S.; Wu, Y.; Deng, Y.; Zhou, L.; Yang, P.; Zheng, Y.; Zhang, D.; Zhai, Z.; Li, N.; Hao, Q.; et al. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors. Oncoimmunology 2019, 8, e1659094. [Google Scholar] [CrossRef] [Green Version]
- Jarosz-Biej, M.; Smolarczyk, R.; Cichon, T.; Kulach, N. Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy. Int. J. Mol. Sci. 2019, 20, 3212. [Google Scholar] [CrossRef] [Green Version]
- Hekim, N.; Cetin, Z.; Nikitaki, Z.; Cort, A.; Saygili, E.I. Radiation triggering immune response and inflammation. Cancer Lett. 2015, 368, 156–163. [Google Scholar] [CrossRef]
- Hanoteau, A.; Newton, J.M.; Krupar, R.; Huang, C.; Liu, H.C.; Gaspero, A.; Gartrell, R.D.; Saenger, Y.M.; Hart, T.D.; Santegoets, S.J.; et al. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. J. Immunother Cancer 2019, 7, 10. [Google Scholar] [CrossRef] [Green Version]
- Demaria, S.; Golden, E.B.; Formenti, S.C. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015, 1, 1325–1332. [Google Scholar] [CrossRef]
- Jang, B.S.; Kim, I.A. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset. Radiother. Oncol. 2017, 124, 403–410. [Google Scholar] [CrossRef]
- Waks, A.G.; Stover, D.G.; Guerriero, J.L.; Dillon, D.; Barry, W.T.; Gjini, E.; Hartl, C.; Lo, W.; Savoie, J.; Brock, J.; et al. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clin. Cancer Res. 2019. [Google Scholar] [CrossRef] [Green Version]
- Drobin, K.; Marczyk, M.; Halle, M.; Danielsson, D.; Papiez, A.; Sangsuwan, T.; Bendes, A.; Hong, M.-G.; Qundos, U.; Harms-Ringdahl, M.; et al. Molecular Profiling for Predictors of Radiosensitivity in Patients with Breast or Head-and-Neck Cancer. Cancers 2020, 12, 753. [Google Scholar] [CrossRef] [Green Version]
- Sjostrom, M.; Staaf, J.; Eden, P.; Warnberg, F.; Bergh, J.; Malmstrom, P.; Ferno, M.; Nimeus, E.; Fredriksson, I. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. Breast Cancer Res. 2018, 20, 64. [Google Scholar] [CrossRef]
- Eschrich, S.A.; Fulp, W.J.; Pawitan, Y.; Foekens, J.A.; Smid, M.; Martens, J.W.; Echevarria, M.; Kamath, V.; Lee, J.H.; Harris, E.E.; et al. Validation of a radiosensitivity molecular signature in breast cancer. Clin. Cancer Res. 2012, 18, 5134–5143. [Google Scholar] [CrossRef] [Green Version]
- Sohn, I.; Kim, J.; Jung, S.H.; Park, C. Gradient lasso for Cox proportional hazards model. Bioinformatics 2009, 25, 1775–1781. [Google Scholar] [CrossRef] [Green Version]
- Wang, H.; Mu, X.; He, H.; Zhang, X.D. Cancer Radiosensitizers. Trends Pharm. Sci. 2018, 39, 24–48. [Google Scholar] [CrossRef]
- De Ruysscher, D.; Niedermann, G.; Burnet, N.G.; Siva, S.; Lee, A.W.M.; Hegi-Johnson, F. Radiotherapy toxicity. Nat. Rev. Dis. Primers 2019, 5, 13. [Google Scholar] [CrossRef]
- Lacombe, J.; Azria, D.; Mange, A.; Solassol, J. Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Rev. Proteom. 2013, 10, 33–42. [Google Scholar] [CrossRef]
- Sindoni, A.; Minutoli, F.; Ascenti, G.; Pergolizzi, S. Combination of immune checkpoint inhibitors and radiotherapy: Review of the literature. Crit. Rev. Oncol. Hematol. 2017, 113, 63–70. [Google Scholar] [CrossRef]
- Gotwals, P.; Cameron, S.; Cipolletta, D.; Cremasco, V.; Crystal, A.; Hewes, B.; Mueller, B.; Quaratino, S.; Sabatos-Peyton, C.; Petruzzelli, L.; et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 2017, 17, 286–301. [Google Scholar] [CrossRef]
- Gentles, A.J.; Newman, A.M.; Liu, C.L.; Bratman, S.V.; Feng, W.; Kim, D.; Nair, V.S.; Xu, Y.; Khuong, A.; Hoang, C.D.; et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 2015, 21, 938–945. [Google Scholar] [CrossRef] [PubMed]
- McDonald, K.A.; Kawaguchi, T.; Qi, Q.; Peng, X.; Asaoka, M.; Young, J.; Opyrchal, M.; Yan, L.; Patnaik, S.; Otsuji, E.; et al. Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients. Ann. Surg. Oncol. 2019, 26, 2191–2199. [Google Scholar] [CrossRef] [PubMed]
- Milo, I.; Bedora-Faure, M.; Garcia, Z.; Thibaut, R.; Perie, L.; Shakhar, G.; Deriano, L.; Bousso, P. The immune system profoundly restricts intratumor genetic heterogeneity. Sci. Immunol. 2018, 3. [Google Scholar] [CrossRef] [PubMed]
- Caswell, D.R.; Swanton, C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017, 15, 133. [Google Scholar] [CrossRef]
- Xu, L.X.; He, M.H.; Dai, Z.H.; Yu, J.; Wang, J.G.; Li, X.C.; Jiang, B.B.; Ke, Z.F.; Su, T.H.; Peng, Z.W.; et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann. Oncol. 2019. [Google Scholar] [CrossRef]
- Wen, P.; Xia, J.; Cao, X.; Chen, B.; Tao, Y.; Wu, L.; Xu, A.; Zhao, G. dbCRSR: A manually curated database for regulation of cancer radiosensitivity. Database (Oxf.) 2018, 2018. [Google Scholar] [CrossRef] [Green Version]
- Galon, J.; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 2019, 18, 197–218. [Google Scholar] [CrossRef]
- Heissig, B.; Rafii, S.; Akiyama, H.; Ohki, Y.; Sato, Y.; Rafael, T.; Zhu, Z.; Hicklin, D.J.; Okumura, K.; Ogawa, H.; et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J. Exp. Med. 2005, 202, 739–750. [Google Scholar] [CrossRef] [Green Version]
- Barker, H.E.; Paget, J.T.; Khan, A.A.; Harrington, K.J. The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat. Rev. Cancer 2015, 15, 409–425. [Google Scholar] [CrossRef] [PubMed]
- Smyth, M.J.; Ngiow, S.F.; Ribas, A.; Teng, M.W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 2016, 13, 143–158. [Google Scholar] [CrossRef] [PubMed]
- Yoshihara, K.; Shahmoradgoli, M.; Martinez, E.; Vegesna, R.; Kim, H.; Torres-Garcia, W.; Trevino, V.; Shen, H.; Laird, P.W.; Levine, D.A.; et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013, 4, 2612. [Google Scholar] [CrossRef] [PubMed]
- Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015, 12, 453–457. [Google Scholar] [CrossRef] [Green Version]
Cancer Type | Variable | HR | 95% CI | p Value |
---|---|---|---|---|
CESC | Clinical Stage | 1.3751 | 0.9999~1.8911 | 0.05 |
Histologic Grade | 0.7737 | 0.4646~1.2881 | 0.32 | |
HNSC | Clinical Stage | 1.0854 | 0.9396~1.2537 | 0.26 |
Histologic Grade | 1.0664 | 0.8763~1.2975 | 0.52 | |
UCEC | Clinical Stage | 1.9276 | 1.6120~2.3035 | <0.05 |
Histologic Grade | 2.7256 | 1.9058~3.8981 | <0.05 | |
THCA | Clinical Stage | 2.8735 | 1.5947~5.1773 | <0.05 |
Histologic Grade | - | - | - | |
BRCA | Clinical Stage | 4.0612 | 1.9292~8.5491 | <0.05 |
Histologic Grade | - | - | - | |
LGG | Clinical Stage | - | - | - |
Histologic Grade | 2.7072 | 1.7316~4.2321 | <0.05 | |
GBM | Clinical Stage | - | - | - |
Histologic Grade | - | - | - |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wen, P.; Gao, Y.; Chen, B.; Qi, X.; Hu, G.; Xu, A.; Xia, J.; Wu, L.; Lu, H.; Zhao, G. Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers. Cancers 2020, 12, 957. https://doi.org/10.3390/cancers12040957
Wen P, Gao Y, Chen B, Qi X, Hu G, Xu A, Xia J, Wu L, Lu H, Zhao G. Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers. Cancers. 2020; 12(4):957. https://doi.org/10.3390/cancers12040957
Chicago/Turabian StyleWen, Pengbo, Yang Gao, Bin Chen, Xiaojing Qi, Guanshuo Hu, An Xu, Junfeng Xia, Lijun Wu, Huayi Lu, and Guoping Zhao. 2020. "Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers" Cancers 12, no. 4: 957. https://doi.org/10.3390/cancers12040957